Navigation Links
Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review
Date:7/13/2009

SAN DIEGO, July 13 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Victory's lead investigational rug, MGX006. If approved, MGX006 will provide patients and healthcare providers the advantage of a proven antiemetic agent combined with a proprietary formulation ideally suited for the treatment of nausea and vomiting.

"Acceptance of the MGX006 NDA is a significant milestone, it demonstrates Victory's ability to grow its commercial portfolio via internal product development in addition to in-licensing products," said Matt Heck, Chief Executive Officer of Victory. "Pending FDA approval, we are planning for a first half of 2010 product launch, allowing Victory to further leverage its 150 person field sales organization. Given many patients suffering from pain also suffer from emesis, there is a good fit between MGX006 and Victory's growing, pain management franchise."

Approximately 25 million prescriptions are written annually in the U.S. for anti-emetic therapeutics. The vast majority of these prescriptions are for traditional, oral solid drug formulations, which can be problematic among patients with emesis.

"We believe the attributes of MGX006 will provide an important alternative for patients suffering from nausea and vomiting of various etiologies," said Dr. Shawn Scranton, Vice President, Scientific Operations. "We look forward to working closely with the FDA on a timely approval."

About Victory Pharma

Founded in 2003, Victory Pharma, Inc. is a privately held specialty pharmaceutical company headquartered in San Diego, CA focused on acquiring, developing, and marketing products to treat pain and related conditions. Victory markets its lead product, NAPRELAN(R) (naproxen sodium) Controlled-Release Tablets and other pain products to pain management specialists, rheumatologists, orthopedic surgeons, and selected primary care physicians through its physician office-based field sales force. Victory is also developing proprietary products for the treatment of chronic pain and common opiate- induced side effects Further information regarding Victory Pharma is available at www.victorypharma.com.

NAPRELAN(R) is a trademark of Elan Corporation, plc.


'/>"/>
SOURCE Victory Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco
2. American College of Chest Physicians Celebrates the Nations Victory for Tobacco Control
3. Mississippi Tobacco Tax Increase is a Victory for Kids and Taxpayers
4. Victory! Colombian Government Cuts Price of Abbotts Lifesaving AIDS Drug Kaletra 55%, Says AHF
5. Hawaii Cigarette Tax Increase Delivers Victory for Kids and Taxpayers
6. Rhode Island Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Highest Cigarette Tax in the Nation
7. LYSOL NASCAR Sponsorship - A Victory for Fans Pit Stops
8. Consumers Win Major Victory Over Seafood Scaremongers
9. Executive Order on Embryonic Stem Cells A Sad Victory of Politics Over Science and Ethics, Says Cardinal Rigali
10. Victory Pharma Announces $45 Million Equity Financing
11. Supreme Court Ruling is a Victory for Consumers Injured by Dangerous Drugs, Says Hissey Kientz, LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create and edit ... the reporting process and provides a familiar interface that does not require additional ...
(Date:4/28/2017)... ... , ... Getting enough sleep affects much more than energy – it also has mental and ... can compromise motor reaction time, which can increase the risk of having a car accident. ... tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... Cypress, California (PRWEB) , ... April 28, 2017 ... ... LED T8 Direct Replace tubes . These lamps offer an instant energy-saving solution ... no need to rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... ... 28, 2017 , ... Early detection and elimination of new ... minimize the cost of development. In this webinar, sponsored by Molecular Devices, an ... for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In the first ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: